Cargando…
Antisense Oligonucleotide-Mediated Terminal Intron Retention of the SMN2 Transcript
The severe childhood disease spinal muscular atrophy (SMA) arises from the homozygous loss of the survival motor neuron 1 gene (SMN1). A homologous gene potentially encoding an identical protein, SMN2 can partially compensate for the loss of SMN1; however, the exclusion of a critical exon in the cod...
Autores principales: | Flynn, Loren L., Mitrpant, Chalermchai, Pitout, Ianthe L., Fletcher, Sue, Wilton, Steve D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854547/ https://www.ncbi.nlm.nih.gov/pubmed/29858094 http://dx.doi.org/10.1016/j.omtn.2018.01.011 |
Ejemplares similares
-
Targeted SMN Exon Skipping: A Useful Control to Assess In Vitro and In Vivo Splice-Switching Studies
por: Flynn, Loren L., et al.
Publicado: (2021) -
Improved Antisense Oligonucleotide Design to Suppress Aberrant SMN2 Gene Transcript Processing: Towards a Treatment for Spinal Muscular Atrophy
por: Mitrpant, Chalermchai, et al.
Publicado: (2013) -
Systematic Approach to Developing Splice Modulating Antisense Oligonucleotides
por: Aung-Htut, May T., et al.
Publicado: (2019) -
Antisense-mediated splice intervention to treat human disease: the odyssey continues
por: Pitout, Ianthe, et al.
Publicado: (2019) -
Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of SMN2 in SMA Type I Fibroblasts
por: Toosaranont, Jarichad, et al.
Publicado: (2022)